Skip to content

TAG and 82 other organizations and 106 individuals representing TB-affected communities and civil society sent an open letter to Johnson & Johnson calling on the company to take urgent action to commit to nonenforcement of the secondary patent on bedaquiline so all countries with high burdens of TB, MDR-TB, and TB/HIV can access generic, quality-assured bedaquiline after the primary patent expires on July 18, 2023.


Back To Top